Ignazio Piseddu

机构：Munich University of Applied Sciences, LMU Klinikum, Comprehensive Cancer Center Erlangen, Ludwig-Maximilians-Universität München · ORCID：0000-0001-8331-9778

发表论文 90 篇 · 总被引 690 次 · h-index 12

代表论文

• Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours (2026 · Nature Biomedical Engineering · 被引 6)
• Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity (2025 · JHEP Reports · 被引 5)
• TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity (2025 · Journal for ImmunoTherapy of Cancer · 被引 2)
• Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab (2025 · Annals of Hepatology · 被引 2)
• Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass) (2026 · Therapeutic Advances in Medical Oncology · 被引 1)
• STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer (2026 · Gastroenterology · 被引 1)